ReViral is a UK-based biotechnology company with a portfolio of drugs to treat Respiratory Syncytial Virus (RSV) infection. RSV currently represents a major unmet medical need in children, the elderly and the immuno compromised.
Our most advanced programme, RV521, is a highly potent, orally-administered inhibitor of RSV fusion protein, and has demonstrated top-line safety and pharmacokinetic data in Phase1 single and multiple ascending dose (SAD and MAD) trials. RV521 has successfully completed a Phase 2a proof-of-concept study in adult volunteers. RV521 will start clinical trials in patients in 2018.
#RSV is a serious respiratory #virus and remains the leading cause of acute lower respiratory tract infections in infants and young children. This #RSVAwarenessMonth, Learn the signs and symptoms of RSV to protect your family: bit.ly/31vQjjA #RSVseason #respiratoryvirus pic.twitter.com/tGdBOWVYAD